Cite
P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT Biomarkers.
MLA
Mezquita, Laura, et al. “P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT Biomarkers.” Journal of Thoracic Oncology, vol. 12, Jan. 2017, p. S1316. EBSCOhost, https://doi.org/10.1016/j.jtho.2016.11.1861.
APA
Mezquita, L., Charrier, M., Auclin, E., Dupraz, L., Remon, J., Planchard, D., Gion, M., Lahmar, J., Gazzah, A., Adam, J., Chaput, N., & Besse, B. (2017). P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT Biomarkers. Journal of Thoracic Oncology, 12, S1316. https://doi.org/10.1016/j.jtho.2016.11.1861
Chicago
Mezquita, Laura, Melinda Charrier, Edouard Auclin, Louise Dupraz, Jordi Remon, David Planchard, Maria Gion, et al. 2017. “P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: Topic: IT Biomarkers.” Journal of Thoracic Oncology 12 (January): S1316. doi:10.1016/j.jtho.2016.11.1861.